BIOMAT Database Logo BIOMAT Database Logo

Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. 2021

Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Academic Trials Promoting Team, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), Brussels, Belgium; Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center - IRCCS, Rozzano (Milan), Italy; Humanitas University, Department of Biomedical Sciences, via Rita Levi Montalcini 4, 20090 Pieve Emanuele - Milan, Italy. Electronic address: elisa.agostinetto@bordet.be.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000082082 Immune Checkpoint Inhibitors Drugs that block negative regulator IMMUNE CHECKPOINT proteins (e.g., PD-1 RECEPTOR and CTLA-4 ANTIGEN) thereby increasing suppressed immune activation in immunotherapies. CTLA-4 Inhibitor,CTLA-4 Inhibitors,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitor,Cytotoxic T-Lymphocyte-Associated Protein 4 Inhibitors,Immune Checkpoint Blockade,Immune Checkpoint Blockers,Immune Checkpoint Inhibition,Immune Checkpoint Inhibitor,PD-1 Inhibitor,PD-1 Inhibitors,PD-1-PD-L1 Blockade,PD-L1 Inhibitor,PD-L1 Inhibitors,Programmed Cell Death Protein 1 Inhibitor,Programmed Cell Death Protein 1 Inhibitors,Programmed Death-Ligand 1 Inhibitors,Blockade, PD-1-PD-L1,CTLA 4 Inhibitor,CTLA 4 Inhibitors,Checkpoint Blockade, Immune,Checkpoint Blockers, Immune,Checkpoint Inhibition, Immune,Checkpoint Inhibitor, Immune,Checkpoint Inhibitors, Immune,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitor,Cytotoxic T Lymphocyte Associated Protein 4 Inhibitors,Inhibitor, PD-1,PD 1 Inhibitor,PD 1 Inhibitors,PD 1 PD L1 Blockade,PD L1 Inhibitor,PD L1 Inhibitors,Programmed Death Ligand 1 Inhibitors
D066126 Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION. Cardiac Toxicity,Cardiac Toxicities,Cardiotoxicities,Toxicity, Cardiac

Related Publications

Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials: An enigmatic discordance resolved.
September 2021, European journal of cancer (Oxford, England : 1990),
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Response to letter entitled: 'Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors'.
August 2021, European journal of cancer (Oxford, England : 1990),
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis.
January 2024, Frontiers in oncology,
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
January 2022, Frontiers in immunology,
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Re: typhoid fever vaccines: systematic review and meta-analysis of randomised clinical trials.
January 2008, Vaccine,
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Rechallenge of immune checkpoint inhibitors: A systematic review and meta-analysis.
September 2021, Critical reviews in oncology/hematology,
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.
May 2024, Journal of the American Heart Association,
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis.
January 2024, Frontiers in immunology,
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Response to letter entitled: Re: Anthropometric indicators of adiposity and risk of primary liver cancer: a systematic review and dose-response meta-analysis.
October 2023, European journal of cancer (Oxford, England : 1990),
Elisa Agostinetto, and Marcello Ceppi, and Marco Bruzzone, and Matteo Lambertini, and Evandro de Azambuja
Response to Letter Entitled "Re: Anthropometric indicators of adiposity and risk of primary liver cancer: a systematic review and dose-response meta-analysis".
October 2023, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!